NextPlat (NXPL) Capital Leases (2023)
NextPlat's (NXPL) quarterly Capital Leases came in at $5000.0 in Q4 2023, down 49.48% quarter-over-quarter from $9897.0 in Q3 2023.
Powered by 
Analysis
NextPlat (NXPL) Capital Leases (2023) Analysis & Trends
NextPlat (NXPL) has reported Capital Leases for 1 consecutive years, with $5000.0 the latest figure, recorded in Q4 2023.
- On a quarterly basis, Capital Leases changed N/A year-over-year to $5000.0 in Q4 2023; TTM through Dec 2023 was $5000.0, a N/A change from a year earlier, with the FY2023 full-year figure at $5000.0, changed N/A from the prior year.
- Capital Leases was $5000.0 for Q4 2023 at NextPlat, down from $9897.0 in the prior quarter.
- Over five years, Capital Leases peaked at $9897.0 in Q3 2023 and troughed at $5000.0 in Q4 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.34 Bn | 38.68 Bn | 2.15 Bn |
| 2 | Viatris | 19.39 Bn | 18.50 Bn | 1.46 Bn |
| 3 | Dr Reddys Laboratories | 9.99 Bn | 9.85 Bn | 396.53 Mn |
| 4 | Amneal Pharmaceuticals | 5.57 Bn | 5.53 Bn | 334.51 Mn |
| 5 | Bausch Health Companies | 2.45 Bn | 1.58 Bn | 2.10 Bn |
| 6 | Ani Pharmaceuticals | 1.70 Bn | 1.34 Bn | 165.89 Mn |
| 7 | Alvotech | 1.66 Bn | 1.52 Bn | 2.56 Mn |
| 8 | Amphastar Pharmaceuticals | 985.90 Mn | 695.77 Mn | 93.47 Mn |
| 9 | Fennec Pharmaceuticals | 434.07 Mn | 392.82 Mn | 17.15 Mn |
| 10 | NextPlat | 24.77 Mn | 12.93 Mn | 4.69 Mn |